Key Drivers
- Margin Expansion
- Strong Cash Flow
- Dilution Risk
AIAI Summary
PGNY is a cash-generative, margin-expanding fertility-benefits platform—not simply a growth story—but its premium valuation hinges on a prompt recovery in treatment utilization; investors should await confirmation of September demand normalization and buybacks that offset heavy stock-based compensation before underwriting a rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Dilution Risk
PGNY shows improving margins, strong cash flow and low debt, but elevated valuation, weakening liquidity/equity, and heavy stock-based compensation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Resistance test
- •Support rebound
PGNY gained 4.5% over the last month and remains constructive above $26.53, with a break above $28.10 bullish and a drop below $25.40 bearish.
Retreated from $27.85 after a support-driven rally
Sentiment & News
Key News Insights:
- •Institutional Buying
- •Analyst Upside
- •Margin Expansion
Progyny attracted new institutional investors and favorable analyst support, reinforcing a positive outlook driven by fertility-benefits leadership, growth, and margin expansion.
The news is broadly positive for PGNY, potentially supporting investor confidence and valuation momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings